JPWO2021178885A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021178885A5 JPWO2021178885A5 JP2022552538A JP2022552538A JPWO2021178885A5 JP WO2021178885 A5 JPWO2021178885 A5 JP WO2021178885A5 JP 2022552538 A JP2022552538 A JP 2022552538A JP 2022552538 A JP2022552538 A JP 2022552538A JP WO2021178885 A5 JPWO2021178885 A5 JP WO2021178885A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- double
- nucleotide sequence
- nucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 89
- 239000002773 nucleotide Substances 0.000 claims 66
- 108091081021 Sense strand Proteins 0.000 claims 31
- 230000000692 anti-sense effect Effects 0.000 claims 27
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 230000002452 interceptive effect Effects 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 9
- 241000700721 Hepatitis B virus Species 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 6
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 5
- 102000053602 DNA Human genes 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 101150010882 S gene Proteins 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 101150003160 X gene Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000000368 destabilizing effect Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986150P | 2020-03-06 | 2020-03-06 | |
| US62/986,150 | 2020-03-06 | ||
| US202063109196P | 2020-11-03 | 2020-11-03 | |
| US63/109,196 | 2020-11-03 | ||
| PCT/US2021/021199 WO2021178885A1 (en) | 2020-03-06 | 2021-03-05 | Modified short interfering nucleic acid (sina) molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515664A JP2023515664A (ja) | 2023-04-13 |
| JPWO2021178885A5 true JPWO2021178885A5 (ko) | 2024-03-14 |
Family
ID=75278356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552538A Pending JP2023515664A (ja) | 2020-03-06 | 2021-03-05 | 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20220364096A1 (ko) |
| EP (1) | EP4121533A1 (ko) |
| JP (1) | JP2023515664A (ko) |
| KR (1) | KR20220163960A (ko) |
| CN (1) | CN115485384A (ko) |
| AU (1) | AU2021230601A1 (ko) |
| BR (1) | BR112022017287A2 (ko) |
| CA (1) | CA3170466A1 (ko) |
| CL (1) | CL2022002379A1 (ko) |
| CO (1) | CO2022014258A2 (ko) |
| IL (1) | IL296045A (ko) |
| MX (1) | MX2022011012A (ko) |
| PE (1) | PE20221578A1 (ko) |
| TW (1) | TW202208625A (ko) |
| WO (1) | WO2021178885A1 (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018332216B2 (en) * | 2017-09-14 | 2024-05-02 | Janssen Biopharma, Inc. | Galnac derivatives |
| CN115485384A (zh) * | 2020-03-06 | 2022-12-16 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸(siNA)分子和其用途 |
| AU2021365812A1 (en) | 2020-10-21 | 2023-05-11 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2023122317A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
| US20230399645A1 (en) * | 2022-05-16 | 2023-12-14 | University Of Massachusetts | Optimized sirna scaffolds |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| WO2024126650A1 (en) | 2022-12-15 | 2024-06-20 | Syngenta Crop Protection Ag | Novel bicyclic-carboxamide compounds useful as pesticides |
| CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110046206A1 (en) * | 2007-06-22 | 2011-02-24 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| EP2601204B1 (en) | 2010-04-28 | 2016-09-07 | Ionis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| MX342731B (es) * | 2011-06-30 | 2016-10-11 | Arrowhead Res Corp | Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b. |
| CN104105790A (zh) * | 2011-11-18 | 2014-10-15 | 阿尔尼拉姆医药品有限公司 | 修饰的RNAi试剂 |
| WO2015125783A1 (ja) * | 2014-02-18 | 2015-08-27 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
| KR20180038465A (ko) * | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| AU2017320582B2 (en) | 2016-09-02 | 2023-11-16 | Arrowhead Pharmaceuticals, Inc | Targeting ligands |
| KR102493872B1 (ko) | 2016-09-02 | 2023-01-30 | 다이서나 파마수이티컬, 인크. | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 |
| EP4219713A3 (en) * | 2017-04-05 | 2023-08-16 | Silence Therapeutics GmbH | Products and compositions |
| CA3083968C (en) * | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| US20210238594A1 (en) * | 2018-05-07 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
| MX2021005357A (es) | 2018-11-08 | 2021-06-30 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos. |
| CN115485384A (zh) * | 2020-03-06 | 2022-12-16 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸(siNA)分子和其用途 |
-
2021
- 2021-03-05 CN CN202180032666.3A patent/CN115485384A/zh active Pending
- 2021-03-05 KR KR1020227034100A patent/KR20220163960A/ko active Search and Examination
- 2021-03-05 IL IL296045A patent/IL296045A/en unknown
- 2021-03-05 TW TW110108015A patent/TW202208625A/zh unknown
- 2021-03-05 EP EP21715377.4A patent/EP4121533A1/en active Pending
- 2021-03-05 JP JP2022552538A patent/JP2023515664A/ja active Pending
- 2021-03-05 PE PE2022001900A patent/PE20221578A1/es unknown
- 2021-03-05 CA CA3170466A patent/CA3170466A1/en active Pending
- 2021-03-05 WO PCT/US2021/021199 patent/WO2021178885A1/en unknown
- 2021-03-05 US US17/194,079 patent/US20220364096A1/en active Pending
- 2021-03-05 AU AU2021230601A patent/AU2021230601A1/en active Pending
- 2021-03-05 MX MX2022011012A patent/MX2022011012A/es unknown
- 2021-03-05 BR BR112022017287A patent/BR112022017287A2/pt unknown
-
2022
- 2022-02-15 US US17/672,268 patent/US11549110B2/en active Active
- 2022-09-01 CL CL2022002379A patent/CL2022002379A1/es unknown
- 2022-10-05 CO CONC2022/0014258A patent/CO2022014258A2/es unknown
- 2022-11-29 US US18/059,561 patent/US20230332153A1/en active Pending
-
2023
- 2023-07-28 US US18/361,363 patent/US20230365970A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7237816B2 (ja) | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 | |
| JP5173793B2 (ja) | マイクロｒｎａ及びそれを阻害する方法 | |
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2023011793A5 (ko) | ||
| JPWO2021178885A5 (ko) | ||
| CN113507920A (zh) | 用于乙型肝炎病毒感染的RNAi剂 | |
| JP2021503941A5 (ko) | ||
| JP2023068035A5 (ko) | ||
| JP2019533472A5 (ko) | ||
| JP2019529406A5 (ko) | ||
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| TWI791868B (zh) | 調節rtel1表現之寡核苷酸 | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| JPWO2020063198A5 (ko) | ||
| JPWO2020243490A5 (ko) | ||
| RU2020118025A (ru) | Нуклеиновая кислота, композиция и конъюгат, содержащие ее, а также способ их получения и применения | |
| JPWO2019175260A5 (ko) | ||
| RU2023129080A (ru) | МиРНК, НАЦЕЛЕННАЯ НА 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗУ 13 ТИПА (HSD17B13), И КОНЪЮГАТ миРНК |